ArticleHuman genomics2025
Identification of potential predictive biomarkers during JAK-inhibitor therapies in rheumatoid arthritis.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of complex miRNA-mRNA interaction networks during JAK inhibitor therapy in rheumatoid arthritis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundTargeted synthetic therapeutics, such as Janus kinase (JAK) inhibitors, have opened up a new platform for the treatment of various diseases, including rheumatoid arthritis (RA). As with all drugs, the efficacy of different medicine may vary from patient to patient, and there may be different side effects if the expected effect is not achieved. In addition to the uncertain success of treatments, they also place a heavy burden on the health care system, making the identification of potential predictive biomarkers for drug optimisation highly valuable.
methodsIn order to identify potential predictive biomarkers, 28 patients with RA were recruited and blood samples were taken twice–before medical treatment and after 6 months of continuous therapy. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples and after RNA isolation, RNA sequencing was performed using high throughput sequencing technology to generate global gene expression data. Validation of target genes was conducted using real-time quantitative PCR methods.
resultsAfter data analyses we examined the gene expression changes between the two sampling time points and responder versus non-responder groups. 225 genes showed significantly different expression between T6 and T0 samples, while 60 and 66 genes showed differential expression between the responder and non-responder patients at T0 and T6 sampling points, respectively. 13 differentially expressed genes were common between two time points and showed the same direction in regulation.
conclusionsBased on our results, several RA-relevant genes were identified, as a result of the JAK-inhibitor treatments in comparison of T6 versus T0 samples. At both time points, the differentially expressed genes between responder and non-responder groups could separate the samples, however, the separation was not clear. The identified 13 common genes could also partially separate the responder and non-responder groups from each other. These sets of genes could be the source of potential biomarkers, which could help predict the responsiveness of patients to JAK inhibitor therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.